Slingshot members are tracking this event:

ZIOPHARM (ZIOP) to launch Phase 1 trial in patients with glioblastoma using the combination of Ad-RTS-IL-12 + veledimex and a selected checkpoint inhibitor in 2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Ad-RTS-hIL-12 + veledimex is a gene therapy candidate for the controlled expression of interleukin 12 (IL-12), a critical protein for stimulating an anti-cancer T-cell immune response, using the RheoSwitch Therapeutic System® (RTS®) gene switch
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 27, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 1 Trial, Glioblastoma, Ad-rts-hil-12, Veledimex, Checkpoint Inhibitor